Following treatment of pFs with CRC-EVs (HCT116, HT29, and SW620) for 48 h prior to TIMP1 immunoprecipitation, immunoblot analysis of the isolated immunocomplexes showed a significant increase in co-immunoprecipitation of CD63 and HSP90AA upon CRC-EV treatment. This evidence concerns the gene CD63 and colorectal carcinoma.